Insider buying last 90 days
No open-market insider purchases were filed for INVA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every INVA insider filing, plotted on the chart in Gekko.Open INVA in Gekko
NASDAQ: INVA
Innoviva (INVA) Stock Analysis & Forecast
Oct 12 close
$21.45+0.24 (+1.1%)
Gekko Brief
AI summaryOct 12 closeThis week's attention around Innoviva centers on valuation and options activity rather than a specific event. Coverage highlights a low P/E ratio of 10.12 against an industry average of 17.64, a P/S ratio of 3.46, and comparisons to Merck as value plays in large-cap pharmaceuticals, alongside commentary questioning whether options traders are signaling something ahead of the stock. An Argus report from 7 October referenced a price of $21.21. No specific earnings, deal, or regulatory news is identified this week.
Shares closed at $21.45, up 1.1%, sitting between the 50-day average of $20.96 and the 200-day average of $21.80, reflecting a mixed trend. The GekkoIndex reads 54.3, placing INVA in the Neutral zone, down 7.3 points over the past five sessions. The stock trades 44.7% below Gekko Fair Value of $38.78, a gap worth noting given the broader valuation discussion in recent coverage.
Innoviva's next earnings date falls on 4 November 2026, 23 days away, inside a typical 20-trading-day holding window; the prior quarter saw EPS of $1.94 against an estimate of $0.57, with a -0.5% reaction, and the company has beaten estimates in 4 of the last 8 quarters. Seasonality over the past 5 years shows the next 20 trading days averaging +7.5%, positive in 5 of those years. No insider, Congress, or unusual options activity is recorded in the current windows, leaving earnings timing and seasonal patterns as the primary points of note.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Innoviva price vs fair value
Close $21.45200-day averageGekko Fair Value $38.78
Innoviva quick facts
- Market cap
- $1.58B
- P/E ratio
- 4.9
- Forward P/E
- 8.5
- EPS, TTM
- $4.28
- Revenue, TTM
- $440.0M
- Profit margin
- 81.2%
- Dividend yield
- —
- Beta
- 0.38
- Volume
- 521,191 avg 928,899
- 1-year return
- +22.9%
- Typical daily move
- ±2.3%
- Typical 20-day move
- ±5.2%
- 50-day average
- $20.96
- 200-day average
- $21.80
- Next earnings
- Nov 4
- Shares outstanding
- 72.25M
Innoviva swing-trade checklist
Innoviva scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $21.45 sits between the 50-day ($20.96) and 200-day ($21.80) averages, or the averages disagree.
See the chart - GekkoIndexmixed
54.3, Neutral
Reading 54.3 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
44.7% below
Price is 44.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+7.5% on average
From this point in the calendar, the next 20 trading days averaged +7.5% over 5 years, rising in 5 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Innoviva stock chart and price history
Innoviva closed at $21.45 on Oct 12, 2026, +22.9% over the past year, inside a 52-week range of $16.52 to $25.15.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +3.8%
- 3 months
- −1.3%
- 6 months
- −10.5%
- 1 year
- +22.9%
The full INVA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open INVA in Gekko
Follow Innoviva through every session
Put INVA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track INVA in GekkoFree for 7 days. No credit card required.
About Innoviva
Innoviva develops and markets medical treatments on a global scale, with a product line centered on once-daily combination inhalers. Its offerings include RELVAR/BREO ELLIPTA, which combines vilanterol with fluticasone furoate; ANORO ELLIPTA, which pairs umeclidinium bromide with vilanterol; and TRELEGY ELLIPTA, which brings together all three drug classes in a single treatment aimed at respiratory conditions.
The company works through partnerships rather than operating alone in every respect. It has an alliance with Sarissa Capital Management LP, and it works with Glaxo Group Limited on an agreement covering the development and sale of daily LABA-based medicines for chronic obstructive pulmonary disease and asthma. These arrangements shape how its therapies reach patients and markets.
Innoviva traces its history to 1996, when it was established under the name Theravance, Inc., later adopting its current name in January 2016. The company is headquartered in Burlingame, California, and its shares are listed on the NASDAQ under the ticker INVA.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- inva.com
Innoviva GekkoIndex: the smart money zone
Innoviva’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.3, in the Neutral zone, down 7.3 points over five sessions.
54.3Neutral
Down 7.3 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 49 | +0.1% | +2.3% | ||
| Accumulation | 240 | +0.4% | +2.1% | ||
| Neutral (current zone) | 331 | 0.0% | +0.8% | ||
| Distribution | 56 | +1.0% | −2.0% | ||
| Selling | 6 | Too few readings yet | |||
Average INVA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the INVA price, zone by zone.Track INVA in Gekko
Is Innoviva stock overvalued? Gekko Fair Value
Innoviva trades 44.7% below Gekko Fair Value of $38.78, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Innoviva shares are worth, recalculated every trading day.
$38.78
Gekko Fair Value, Oct 10, 2026
44.7% Undervalued
At the end of Aug 2026 the price was 31.5% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open INVA in Gekko
Innoviva insider and Congress trading
No open-market insider purchases were filed for Innoviva, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in INVA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for INVA, plotted on the chart in Gekko.Open INVA in Gekko
Buybacks
Innoviva has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $30.91M
- As a share of market cap
- 1.95%
- Trailing four quarters
- $55.90M
From company filings.
Innoviva earnings: next date and track record
Innoviva reports on Nov 4, 2026 (23 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 4, 2026
23 days away
- EPS estimate
- $0.52
- Revenue estimate
- $115.3M
4 of 8reports beat the EPS estimate
±2.8%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Mar 4, 2026 | $1.94 est $0.57 | — | −0.5% |
| Nov 5, 2025 | $1.08 est $0.46 | $107.8M est $101.5M | +13.4% |
| Aug 6, 2025 | $0.77 est $0.57 | $100.3M est $90.88M | +0.1% |
| May 6, 2025 | −$0.74 est $0.33 | $88.63M est $82.67M | 0.0% |
| Feb 26, 2025 | $0.26 est $0.41 | $91.81M est $92.59M | −2.7% |
| Nov 6, 2024 | $0.12 est $0.27 | $89.51M est $88.15M | +2.9% |
| Jul 31, 2024 | −$0.55 est $0.24 | $103.4M est $74.69M | +1.6% |
| May 8, 2024 | $0.46 est $0.17 | $80.96M est $68.00M | −1.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Innoviva stock forecast and analyst price targets
Analysts’ average 12-month price target for Innoviva is $35.00, +63.2% from the last close, from 4 firms rating the stock in the last 90 days.
$35.00consensus 12-month target, +63.2% from the last close
Now $21.45Avg $35.00
Low $34High $46
Each firm’s latest rating in the last 90 days: 4 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 23 | Oppenheimer | $35 | +63.2% |
| Aug 20 | Cantor Fitzgerald | $34 | +58.5% |
| Aug 10 | H.C. Wainwright | $46 | +114.5% |
| Aug 6 | Cantor Fitzgerald | $34 | +58.5% |
| Aug 5 | BTIG | $42 | +95.8% |
+0.8%average 20-day move after past Neutral readings
+7.5%average move over the next 20 trading days in the last 5 years
±2.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Innoviva seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Innoviva averaged +7.5% across the last 5 years, rising in 5 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.3% | 3 of 5 |
| Next 10 trading days | +0.5% | 3 of 5 |
| Next 15 trading days | +1.8% | 4 of 5 |
| Next 20 trading days | +7.5% | 5 of 5 |
| Next 30 trading days | +4.8% | 3 of 5 |
For scale, INVA’s typical 20-trading-day move in either direction is about 5.2%.
Innoviva market cap and key statistics
Innoviva’s market cap is $1.58B, with a P/E ratio of 4.9 and revenue of $440.0M over the last twelve months.
Valuation
- Market cap
- $1.58B
- P/E ratio
- 4.9
- Forward P/E
- 8.5
- EPS, TTM
- $4.28
- Gekko Fair Value
- $38.78
Trading
- Volume
- 521,191
- Avg volume, 20 days
- 928,899
- 52-week high
- $25.15
- 52-week low
- $16.52
- Shares outstanding
- 72.25M
Financials
- Revenue, TTM
- $440.0M
- Profit margin
- 81.2%
- Return on equity
- 36.7%
- Quarterly earnings growth, YoY
- +590.0%
Risk and income
- Beta
- 0.38
- Typical daily move
- ±2.3%
- Typical 20-day move
- ±5.2%
Innoviva stock news this week
Coverage of Innoviva this week reads positive: 2 positive, 2 neutral and 0 negative headlines.
- Do Options Traders Know Something About Innoviva Stock We Don't?Zacks Investment Research, Oct 12
- Enterprise value to EBITDA forward of Innoviva, Inc. – BX:HVETradingView, Oct 12
- Innoviva, Inc. (INVA) Stock ForecastsYahoo! Finance Canada, Oct 11
- Is Innoviva (INVA) Undervalued As Zacks Flags Its Value Appeal?Yahoo Finance, Oct 8
- INVA vs. MRK: Which Stock Is the Better Value Option?Zacks Investment Research, Oct 8
- Should Value Investors Buy Innoviva (INVA) Stock?Yahoo Finance Singapore, Oct 8
Innoviva peers
Innoviva’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Innoviva stock FAQ
What is Innoviva’s market cap?
Innoviva’s market cap is $1.58B at the Oct 12, 2026 close of $21.45, with 72.25M shares outstanding. The shares trade on a P/E ratio of 4.9.
What is the Innoviva stock forecast?
The consensus analyst 12-month price target for Innoviva is $35.00, +63.2% from the last close. Of the 4 firms that rated the stock in the last 90 days, 4 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Innoviva stock overvalued or undervalued?
On Gekko’s estimate Innoviva is undervalued: the Oct 12, 2026 close of $21.45 is 44.7% below Gekko Fair Value of $38.78. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Innoviva report earnings next?
Innoviva is expected to report on Nov 4, 2026 (23 days away). Analysts expect earnings of $0.52 per share on revenue of $115.3M. Innoviva beat the earnings estimate in 4 of its last 8 reports, moving 2.8% on average across the report.
What is Innoviva’s 52-week high and low?
Innoviva’s 52-week high is $25.15 and its 52-week low is $16.52; it closed at $21.45 on Oct 12, 2026, +22.9% over the past year.
Is Innoviva stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and seasonality), 2 as mixed (trend and gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Innoviva the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.